Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 圣湘生物科技股份有限公司是以自主创新基因技术为核心，集诊断试剂、仪器、第三方医学检验服务为一体的体外诊断整体解决方案提供商，在科创板上市（股票代码：688289），入选全球医疗器械企业TOP100榜单，上榜中国医药工业百强。公司致力于成为基因科技普惠者，服务国家精准医疗体系和分级诊疗体系建设，是国家基因检测技术应用示范中心、感染性疾病及肿瘤基因诊断技术国家地方联合工程研究中心、国家企业技术中心、国家技术创新示范企业、国家级博士后科研工作站单位、国家知识产权示范企业。作为国内分子诊断龙头企业，公司正在加速向体外诊断国际领军企业转变，向世界一流企业迈进。 公司总部位于长沙，打造了长沙、上海、北京三大产业基地，在成都等全国主要城市和美国、英国、法国、印尼、菲律宾、泰国等全球重要区域设立了分子公司或分支机构。 公司秉承为全世界人民提供用得起、用得好的基因技术、产品和服务的使命，以推动基因技术高精化、简便化、自动化、移动化、系统化“五化”建设为核心，公司自主开发了高精度“磁珠法”、快速简便“一步法”、通用型“全自动统一样本处理”“POCT移动分子诊断”等一系列核心技术，构建了荧光定量PCR、多重PCR技术、基因芯片、基因测序、移动分子诊断、核酸质谱、免疫检测、生物信息等一系列技术平台，获国家科技进步二等奖、中国专利奖等国家级重大奖项近60项，承担国家“十二五”“十三五”重大科技专项等国家级和省级重大项目50余项，逐步构建了基因技术应用普适化、全场景化的新生态，引领国内行业技术赶超国际先进水平，有力打破进口垄断，推动基因技术由医疗机构个别科室应用向多科室应用、大医院高端实验室应用向包括基层医疗机构在内的各个层级医院应用、少数领域应用向全场景应用转变。 公司全力打造精品工程，研发了传染病防控、妇幼健康、血液安全、癌症防控、伴随诊断、农牧科技等一系列性能赶超国内外先进水平的产品1000余种，可提供各类检测服务2200余项，形成了集试剂、仪器、测序服务、第三方医学检验服务、分子实验室共建等为一体的全产业链系统解决方案，产品服务全球160多个国家和地区，累计提供超三十亿人次的检测产品。 公司秉承科技惠民初心，积极践行ESG，在国内外多起公共卫生事件、灾难援助、民生工程中，累计捐赠3.1亿余元现金及物资。 公司将始终坚持“创新+服务”双轮驱动，坚守“每盒每剂，但求高精高质；一诊一断，当思人命关天”的企业担当，研发出更多老百姓用得起、用得好的基因技术、产品和服务，输出全球惠民“圣湘方案”，助力我国抢占世界基因技术制高点和人类卫生健康共同体建设，努力推动基因科技成为服务人类健康的中坚力量。
Main Business 以自主创新基因技术为核心，集诊断试剂和仪器的研发、生产、销售,以及第三方医学检验服务于一体的体外诊断整体解决方案
Legal Representative 戴立忠
Top Executives
董事长：戴立忠
董事：范旭,彭铸,赵汇,喻霞林,方媛,刘佳
独立董事：肖朝君,王善平,曹亚,乔友林
Top 5 Shareholder
Shareholder name Nature Holding Date
戴立忠流通A股32.25%31/03/2024
湖南圣维投资管理有限公司流通A股6.32%31/03/2024
陈文义流通A股5.59%31/03/2024
朱锦伟流通A股4.45%31/03/2024
中国银行股份有限公司－易方达医疗保健行业混合型证券投资基金流通A股2.48%31/03/2024
Company Secretary 黄强
Solicitors 湖南启元律师事务所
Auditors 中审众环会计师事务所（特殊普通合伙）
Tel No 0731-88883176-6018
Fax No 0731-84223503
Website www.sansure.com.cn
Email dmb@sansure.com.cn
Company Address
Register: 湖南省长沙高新技术产业开发区麓松路680号
Office: 湖南省长沙高新技术产业开发区麓松路680号
Listing Date 28/08/2020
Shares Capital
Shares Capital: 589,803,290
Total A Share: 589,803,290
Listed A Share: 589,803,290
Non-tradable A Share: 0
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.620
DPS(RMB)* ¥ 0.462
NBV Per Share(RMB)* ¥ 12.237
Market Capitalization(RMB) 10.906B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.